WellCare, Centene reportedly interested in Aetna’s Medicare Advantage business

Aetna is looking to jettison its Medicare Advantage plans in order to placate antitrust concerns at the Department of Justice over its proposed merger with Humana, and Reuters is reporting at least two companies are competing for that portfolio.

Sources “familiar with the matter” say WellCare and Centene have submitted for bids for plans that cover around 350,000 patients, with a possible sale price of $1 billion.

To read more on the potential sale and how it may affect regulators’ final decision on the Aetna-Humana deal, click on the link below: 

Around the web

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Trimed Popup
Trimed Popup